Compare Natera Inc. Common Stock (NTRA) vs Nvidia Corp (NVDA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Natera Inc. Common Stock vs Nvidia Corp — how do they compare? Natera Inc. Common Stock trades at $393.27 (market cap $57.03B), while Nvidia Corp trades at $217.44 (market cap $5.52T). The key difference: Nvidia Corp is far larger — about 96.8× Natera Inc. Common Stock's market cap, and Nvidia Corp pays a 0.44% dividend while Natera Inc. Common Stock pays none. Which is the better fit depends on your goals — on Pluang, investors hold Natera Inc. Common Stock for 0 Days and Nvidia Corp for 116 Days on average.
| NTRA | NVDA | |
|---|---|---|
Market Cap | $57.03B | $5.52T |
Volume | 1,131,157 | 84,036,941 |
Sector | Health | Technology |
52-Week High | $425.64 | $239.27 |
52-Week Low | $179.42 | $165.17 |
Typical Hold Time | 0 Days | 116 Days |
Enterprise Value | $56.18B | $5.49T |
Dividend Yield | — | 0.44% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
NTRA trades at $395.66, down 0.53% today but remains near recent highs. The stock shows mixed technical signals with neutral momentum indicators. Fundamentally, the company demonstrates strong revenue growth ($2.31B in 2025, projected $2.7B in 2026) but continues to operate at a net loss (-$208M in 2025). Recent positive developments include FDA Breakthrough Device designation for its multi-cancer detection assay and regulatory approval in Japan for Signatera.
NTRA presents a growth story with significant analyst support (89% buy ratings) but carries execution risks. The stock trades at premium valuations (P/S 20.48) while still unprofitable. Key catalysts include clinical trial progress and international expansion, though investors face risks from ongoing losses and competitive pressures in precision medicine.
NVIDIA (NVDA) trades at $228.52, up 0.97% with strong fundamental performance including 55.84% net profit margin and consistent earnings beats. The stock shows bullish technical signals with support at $225 and resistance at $228. Revenue growth accelerated to $130.5B in 2025, while analyst consensus remains strongly bullish with a $339.17 price target representing 48% upside potential.
NVIDIA's AI leadership and expanding market position support continued growth, though valuation multiples remain elevated. Key risks include increased competition and potential market saturation in AI chips. The company's strong cash flow generation and institutional support provide fundamental backing for long-term investors despite near-term volatility concerns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Natera Inc. Common Stock
Natera, Inc. develops and provides cell-free DNA-based genetic testing across women's health, oncology, organ health, and rare disease, with flagship products including Panorama for noninvasive prenatal screening and Signatera for cancer recurrence monitoring.
Read more on NTRA →About Nvidia Corp
NVIDIA Corporation designs, develops, and markets three dimensional (3D) graphics processors and related software. The Company offers products that provides interactive 3D graphics to the mainstream personal computer market.
Read more on NVDA →
